NLRP3 and colitis: Another study has shown that Gal-3 inhibitor DAVANAT® reduces cholangitis induced by Novosphingobium aromaticivorans [138] and DSS-induced colitis [44] by reducing the activation of NLRP3 inflammasome and expression of IL-1β in macrophages.